Virtu Financial LLC Increases Position in Vistagen Therapeutics, Inc. (NASDAQ:VTGN)

Virtu Financial LLC lifted its stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) by 30.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 20,210 shares of the company’s stock after acquiring an additional 4,722 shares during the period. Virtu Financial LLC owned 0.07% of Vistagen Therapeutics worth $61,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in VTGN. Valence8 US LP bought a new position in Vistagen Therapeutics in the third quarter worth about $103,000. HighTower Advisors LLC bought a new position in shares of Vistagen Therapeutics during the 3rd quarter worth approximately $64,000. Blair William & Co. IL lifted its position in Vistagen Therapeutics by 29.2% during the second quarter. Blair William & Co. IL now owns 88,466 shares of the company’s stock valued at $308,000 after acquiring an additional 20,000 shares during the last quarter. Jane Street Group LLC acquired a new stake in Vistagen Therapeutics in the third quarter valued at approximately $59,000. Finally, American Century Companies Inc. grew its holdings in Vistagen Therapeutics by 49.1% in the second quarter. American Century Companies Inc. now owns 30,315 shares of the company’s stock worth $105,000 after purchasing an additional 9,984 shares during the last quarter. 78.39% of the stock is currently owned by hedge funds and other institutional investors.

Vistagen Therapeutics Stock Performance

Shares of VTGN stock opened at $2.50 on Friday. Vistagen Therapeutics, Inc. has a fifty-two week low of $2.22 and a fifty-two week high of $5.86. The firm has a market capitalization of $69.61 million, a price-to-earnings ratio of -2.02 and a beta of 0.82. The stock’s 50-day simple moving average is $2.81 and its 200-day simple moving average is $3.20.

Analyst Ratings Changes

Separately, William Blair raised Vistagen Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th.

Vistagen Therapeutics Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.